Armen Garo H's Form 4/A amendment
AmendedMiNK Therapeutics, Inc. (INKT) · filed May 26, 2023
- Accession no.
- 0000950170-23-024568
- Filed
- May 26, 2023
- Rule 10b5-1 plan
- Not checked
- Original filed
- May 5, 2023
This filing lists no transactions. It carries over 1 transaction from the original filing that it did not restate. Open-market sales total $95.0K.
This amendment restates part of 0000950170-23-018413 (filed May 5, 2023). The transactions it did not restate still count and are listed below.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Armen Garo HCIK 0000935679 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Carried over from the original filing
This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.
From 0000950170-23-018413 (filed May 5, 2023).
Non-derivative securities (Table I)
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 5, 2023 | Common Stock | SSaleDisposed | −100,000 | $0.95 | −$95,000 | 1,866,400 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
On May 5, 2023, Garo Armen, the CEO and Chairman of Agenus, disclosed a transaction involving 100,000 MiNK Therapeutics shares. He agreed to sell these shares to Agenus at his original purchase price, which was lower than the market price at the time of the proposed sale. This action was taken to prevent any perception of Dr. Armen benefitting from low-cost purchases while Agenus was buying at higher prices in separate transactions. However, due to the shares being in Dr. Armen's IRA account, their transfer was prohibited, leading the broker to reverse the sale and decline Agenus' payment. Consequently, the MiNK Therapeutics shares were returned to Dr. Armen, and the sale price was given back to Agenus. This amendment accounts for the changes in Dr. Armen's share ownership following the reversal of this transaction.